Medical Doctor Program year 2025 Reported 2023–2025 Source: CMS Open Payments, 2026 publication

Esosa Adah

Pediatrics Kansas City, MO Medical Doctor

NPI 1831650514 CMS profile 11450374

2401 Gillham Rd, Kansas City, MO 64108

Open in the dashboard

General payments

$8,228

118 records reported · program years 2023–2025

Research payments

$0

Paid to them · None reported · program years 2023–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Esosa Adah of Kansas City, MO is reported in the CMS Open Payments database as having received $8,228 across 118 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 98th percentile of Pediatrics profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

3 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $6,819 90
2024 General $769 17
2023 General $640 11

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Esosa Adah
  • Pediatrics median
  • Middle half of Pediatrics
  • National median

In program year 2025, general payments to Esosa Adah were reported at $6,819. Among 22,296 Pediatrics profiles paid that year, the median was $97 and the middle half received between $37 and $210.

Show as a table
Year Esosa Adah Pediatrics median Middle half National median
2019 $0 $86 $31–$183 $163
2020 $0 $49 $22–$110 $114
2021 $0 $68 $27–$158 $132
2022 $0 $77 $30–$173 $149
2023 $640 $88 $33–$190 $160
2024 $769 $94 $34–$206 $164
2025 $6,819 $97 $37–$210 $169

Breakdown

Who paid General payments · program years 2023–2025
  1. Galderma Laboratories, L.P. $2,515 11 payments
  2. Genzyme Corporation $2,288 12 payments
  3. AstraZeneca Pharmaceuticals LP $845 13 payments
  4. Regeneron Healthcare Solutions, Inc. $522 13 payments
  5. GlaxoSmithKline, LLC. $481 19 payments
  6. ARS Pharmaceuticals Operations, Inc. $315 7 payments
  7. Takeda Pharmaceuticals U.S.A., Inc. $303 8 payments
  8. Novartis Pharmaceuticals Corporation $206 11 payments
  9. Aimmune Therapeutics, Inc. $175 1 payment
  10. CSL Behring $165 7 payments
  11. Other $413 16 payments

Every payment, record by record

What the payments were for General payments · program years 2023–2025
  1. Food and Beverage $4,457 113 payments
  2. Consulting Fee $3,529 2 payments
  3. Honoraria $175 1 payment
  4. Travel and Lodging $68 2 payments
Products named General payments · program years 2023–2025
  1. NEMLUVIO $2,501 10 payments
  2. DUPIXENT Immunology $1,008 12 payments
  3. NUCALA $342 13 payments
  4. FASENRA $332 7 payments
  5. NEFFY $315 7 payments
  6. DUPIXENT Immunology And Inflammation $293 8 payments
  7. TEZSPIRE $258 3 payments
  8. DUPIXENT Inflammation And Immunology $230 5 payments
  9. HYQVIA $190 4 payments
  10. PALFORZIA $175 1 payment
  11. Other $1,246 44 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Records

118 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record